{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"31.9","upperLimit":"68.1","value":"50.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"Response was assessed using International Myeloma Working Group (IMWG) Criteria. CR was defined as negative immunofixation in serum and urine and disappearance of any soft tissue plasmacytomas and \\< 5% plasma cells in bone marrow. VGPR was defined as serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \\< 100 mg per 24 hours.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ixazomib 4 mg, capsules, orally on Days 1, 8, and 15 plus lenalidomide 25 mg, capsule, orally, once daily on Days 1 through 21 and dexamethasone 40 mg, tablet, orally on Days 1, 8, 15, and 22 of a 28-day cycle up to 32 cycles.","id":"OG000","title":"Ixazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg"}],"paramType":"NUMBER","populationDescription":"Response-evaluable analysis set was defined as all full analysis set (FAS) participants with measurable disease at baseline, and at least one postbaseline response assessment.","reportingStatus":"POSTED","timeFrame":"Up to approximately 33 months","title":"Percentage of Participants With Very Good Partial Response (VGPR) or Better Response (Complete Response (CR) + VGPR)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}